Advances in Clinical and Experimental Medicine

27/03/2026

🚀Recently published🚀

Effectiveness of modified ultrasound-guided ilioinguinal and iliohypogastric nerve blocks for postoperative pain control in transinguinal inguinal hernia repair

➡️Ultrasound-guided lower abdominal nerve block significantly improves postoperative pain control in elderly patients undergoing inguinal hernia repair, with consistently lower VAS pain scores during and after surgery.
➡️Modified USG nerve block reduces reliance on systemic analgesics and opioids, supporting safer perioperative pain management in older patients with multiple comorbidities.
➡️Enhanced patient comfort and satisfaction achieved through targeted regional anesthesia, facilitating early mobilization and improved recovery outcomes after transinguinal hernia surgery.
➡️Effective and feasible pain management strategy for geriatric surgery: combining ultrasound-guided nerve block with local anesthetic injection offers a clinically valuable approach for inguinal hernia repair in elderly populations.

🔗Read the article: https://advances.umw.edu.pl/en/ahead-of-print/205614/

27/03/2026

📢From Bench to Bedside: Advances in Neuroinflammation and CNS Disorder Research 📢

📢 Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on Neuroinflammation in CNS Disorders 📢

The editors of this special collection invite submissions exploring the latest advances in clinical and experimental research on neuroinflammation in the central nervous system (CNS). Neuroinflammation is at the forefront of neuroscience, shaping our understanding of CNS disorders such as neurodegenerative disease, psychiatric disorders, and traumatic brain injuries. This collection aims to unite diverse perspectives, fostering insights into the complex cellular and molecular mechanisms driving neuroinflammatory processes. We encourage the submission of original research, meta-analyses, and comprehensive review articles that shed light on diagnostic, therapeutic, and mechanistic aspects of CNS inflammation.
We are particularly interested in manuscripts that explore the interplay between immune cells, neurons, and glia, with a focus on translational research. Contributions detailing innovative diagnostic approaches, therapeutic targets, or computational models are highly welcome. Join this effort to advance the boundaries of neuroinflammation research and contribute to groundbreaking findings that bridge laboratory and clinical neuroscience.

🧠Advances in Clinical and Experimental Medicine is therefore seeking original papers for a Special Collection focused on the following themes:

➡️Neuroimmune Interactions in Health and Disease
➡️Cellular and Molecular Pathways of Neuroinflammation
➡️Neuroinflammation and Neurodegeneration: Cause or Consequence?
➡️Innovative Imaging and Biomarkers for CNS Inflammation
➡️Therapeutic Interventions Targeting Neuroinflammation
➡️Role of Microglia and Astrocytes in Neuroinflammatory Diseases

🔗MORE INFORMATION
https://advances.umw.edu.pl/en/neuroinflammation-in-cns-disorders



Masaru Tanaka

26/03/2026

🦚We are so proud🦚

Our Deputy Editor, Prof. Robert Śmigiel, discusses his work [ENGLISH VERSION BELOW THE LINK]

https://www.umw.edu.pl/pl/aktualnosci/pracujemy-dla-dobra-ludzi

1. Role at Wroclaw Medical University

Head of the Department and Clinic of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases at Wroclaw Medical University; Head of the University Center for Rare Diseases in Wroclaw; Deputy Editor-in-Chief of Advances in Clinical and Experimental Medicine; specialist in pediatrics, clinical genetics, neonatology, and metabolic pediatrics.

2. Main research interests

My research focuses on genetically determined rare diseases, developmental disorders, congenital anomalies, and metabolic diseases in children. This includes studies on etiology, pathogenesis, diagnostics, and therapeutic management, including precision medicine approaches. I am also interested in the causes of intellectual disability, including prenatal teratogenic factors affecting the fetus, such as fetal alcohol spectrum disorders.

3. Why did this field become the most important to you?

Rare diseases affect approximately 8% of the population—around 30 million people in Europe and 3 million in Poland. They are among the most common causes of hospitalization and a leading cause of infant mortality. This represents a medical, social, and economic challenge that significantly impacts entire families.

My sustained clinical and scientific focus on pediatrics, my personal values, early social engagement in support groups for people with disabilities, and a desire to connect scientific outcomes with societal benefit—along with a degree of chance—led me to focus on the underserved and often marginalized field of rare diseases in children.

The outcomes of my work include: identification of new human diseases causing developmental disorders; elucidation of pathogenic mechanisms and therapeutic targets; shortening diagnostic pathways for patients with rare diseases; development of diagnostic and therapeutic recommendations; improving quality of life for patients and their families; establishing parent-led organizations; organizing conferences; identifying family needs; and disseminating knowledge and training healthcare professionals.

4. Which of your achievements do you consider the most groundbreaking or inspiring?

One of the most groundbreaking achievements for me was the description of a new neurodevelopmental rare disease in a newborn with severe peripheral and central nervous system involvement, along with the identification of a novel pathogenic pathway in human development (involving the gene neurofascin – NFASC). I also consider my contribution to developing international recommendations in rare diseases, in collaboration with global scientific and clinical experts, to be highly significant.

5. Which discovery, idea, or publication has most influenced your scientific thinking?

The idea that science should directly benefit patients with rare diseases has been fundamental to my thinking. The work on defining phenotypes of rare diseases in children, collaboration with parent organizations, and the empathy toward patients demonstrated by Professor Raoul Hennekam (Amsterdam) have been a constant source of inspiration.

A particularly influential publication for me was:
Hennekam RC, Biesecker LG. Next-generation sequencing demands next-generation phenotyping. Hum Mutat. 2012;33(5):884–886.

6. How can your research impact everyday life or the development of technology/society?

The key contributions of my work in rare diseases include:

Defining new and redefining known rare diseases in terms of their pathogenic mechanisms
Advancing knowledge of human biology and potential therapeutic strategies
Developing clinical recommendations and guidelines (e.g., for Mowat-Wilson syndrome, Pitt-Hopkins syndrome, Schaaf-Yang syndrome, Prader-Willi syndrome, Down syndrome, Kabuki syndrome, 22q11.2 deletion syndrome, fetal alcohol spectrum disorders (FASD), congenital disorders of glycosylation (CDG), and other ultra-rare syndromes)
Improving care for children with rare diseases and developmental disorders at both national and international levels
Supporting the creation and education of patient and parent organizations through meetings and conferences

The beneficiaries of my research include:

Primarily the 3 million people in Poland affected by rare diseases and their families
Healthcare professionals working with these patients (physicians, nurses, therapists, dietitians, psychologists, public health specialists)
Policymakers at various institutional levels, who rely on scientific data to improve healthcare systems for rare disease patients
7. If you had unlimited resources and a team, what project would you pursue?

My scientific, clinical, and social ambition is to develop precision medicine approaches for rare diseases, including discovering new targeted therapies and advancing gene therapy.

8. One piece of advice for young people considering a scientific career

Science that serves people is my passion and motivation. Science exists for the benefit of humanity—never lose sight of that. Throughout your scientific journey, remember that we work for the good of others, and remain socially sensitive in your research.

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
Robert Stanisław Śmigiel
Donata Kurpas
Advances in Clinical and Experimental Medicine

Aktualności | 20.03.2026 Pracujemy dla dobra ludzi Udostępnij Poprosiliśmy naukowców UMW, którzy znaleźli się w najnowszej edycji rankingu World’s Top 2% Scientists, o wypełnienie krótkiego kwestionariusza dotyczącego głównych obszarów badawczych i osiągnięć naukowych. Wszyscy otrz...

26/03/2026

📢Social Prescribing Day – March 26, 2026 📢

Social Prescribing Day is an annual celebration of the people, organizations and communities who make social prescribing happen. Since 2019, thousands of local, national and international organizations, link workers, medical professionals, academics and students have taken part across the world. Every year, we have joined together to hold events, share ideas and highlight the impact of social prescribing on people and communities. Together, we want to raise awareness of what social prescribing is, how it works, and how it changes lives.

What is Social Prescribing?

💡In short: Connecting people to activities, groups and support that improve health and wellbeing. Many things that affect our health can’t be treated by doctors or medicine alone – like loneliness, debt, or stress due to financial pressures or poor housing. Social prescribing connects people to non-medical support to address these issues and other unmet needs.

💡Social prescribing is a person-centered approach to health and wellbeing that enables healthcare professionals to connect individuals with non-medical support in their communities. Rather than focusing solely on clinical treatments, social prescribing addresses the wider social determinants of health – such as loneliness, housing insecurity, unemployment, physical inactivity, and mental distress – that strongly influence health outcomes. Through referral pathways, typically involving trained link workers, individuals are supported to identify personal goals and engage with community-based activities including social groups, physical activity, arts, volunteering, and practical support services. This model shifts care from a disease-focused framework toward a holistic understanding of “what matters” to the person.

💡The Social Prescribing Academy emphasizes that effective social prescribing requires strong partnerships between healthcare systems, local authorities, voluntary organizations, and communities. By embedding social prescribing within primary care and public health strategies, the approach aims to improve mental and physical wellbeing, reduce health inequalities, and alleviate pressure on healthcare services. While evidence continues to grow, the Academy highlights the importance of workforce development, sustainable funding, and robust evaluation to scale social prescribing responsibly. Overall, social prescribing represents a systemic shift toward integrated, community-driven care that complements medical treatment and supports long-term population health.

🔗More about social prescribing
https://socialprescribingacademy.org.uk/what-is-social-prescribing/
https://socialprescribingacademy.org.uk/how-we-can-support-you/supporting-you/

🔗A short video about social prescribing
https://www.youtube.com/watch?v=6EX9-CVmo7o

🔗Scientific evidence supporting social prescribing
https://socialprescribingacademy.org.uk/nasps-evidence-reports/

🔗National Academy for Social Prescribing (UK)
https://socialprescribingacademy.org.uk/what-is-social-prescribing/social-prescribing-day-2026/

25/03/2026

🚀Recently published🚀

Potential salivary protein biomarkers for the identification of mild traumatic brain injury: A systematic review

➡️This systematic review identifies salivary protein biomarkers with potential diagnostic value for the identification of mild traumatic brain injury (mTBI).
➡️Findings indicate that specific salivary proteins – including ALOX5, ITGB2, ADRB2, and HRH1 – show consistent expression across different mTBI injury mechanisms.
➡️Salivary biomarkers represent a promising noninvasive approach for early mTBI detection, particularly in settings where advanced neuroimaging is unavailable.

https://advances.umw.edu.pl/en/ahead-of-print/206004/

25/03/2026

📢New Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on

Revolutionizing Cancer Treatment: Navigating the Intricate Landscape of Cellular Signaling Networks📢

🧠Cancer arises from disruptions in the intricate cell signaling networks that drive tumor cell behavior. Chemotherapy and immunotherapy are the main cancer treatment approaches, but the complexity of these signaling networks often hinders the success of targeted therapies. Understanding the cell signaling networks involved in cancer development and progression is crucial. Challenges like drug resistance and metastasis underscore the need for novel approaches targeting key signaling networks for more effective cancer treatment.

🧠Immunotherapy has shown promise by stimulating the patient's immune system but only benefits a subset of patients. Current research has identified many signaling pathways influencing cancer cell growth, spread, and drug resistance. However, the complexity of these signaling networks limits the successful clinical application of individual molecular targets. An in-depth understanding of the functions and regulation of key signaling networks associated with tumor progression is essential to develop new chemotherapies and targeted treatments.

🧠This research initiative seeks submissions on topics like:

1. Immune regulatory networks influencing cancer progression and prognosis
2. Signaling pathways involved in cancer initiation and metastasis
3. Biomarkers for predicting responses to immunotherapy and chemotherapy
4. Crucial cell signaling networks governing immune responses
5. Using multi-omics to reveal critical cancer signaling networks

🔗MORE INFORMATION
https://advances.umw.edu.pl/en/revolutionizing-cancer-treatment

24/03/2026

📢Call for Submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on Closing the Implementation Gap in Cardiometabolic Prevention in Primary Care📢

Despite the availability of evidence-based guidelines, the implementation of cardiometabolic prevention strategies in routine clinical practice remains suboptimal. Persistent gaps between recommended standards of care and real-world management of cardiovascular and metabolic risk have been consistently reported, particularly in primary care and general internal medicine settings.
This Special Issue of Adv Clin Exp Med aims to explore the scope, determinants, and consequences of the implementation gap in cardiometabolic prevention, as well as evidence-based strategies to address it. We invite original research and high-quality reviews that examine how preventive recommendations are translated into everyday practice, and which factors influence successful or failed implementation.

🧠Topics of interest include, but are not limited to:

➡️Real-world adherence to cardiovascular and cardiometabolic prevention guidelines

➡️System-, organizational-, and physician-level determinants of preventive care

➡️Barriers and facilitators of risk factor control in primary care settings

➡️Application of implementation science frameworks in general and internal medicine

➡️Population-based studies, registry analyses, and real-world data on prevention outcomes

➡️Comparative analyses of implementation strategies across healthcare systems or regions

🧠We particularly welcome multidisciplinary contributions integrating clinical medicine, epidemiology, public health, and health services research. Both quantitative and qualitative approaches, including mixed-methods studies, are encouraged.

🧠Keywords
preventive cardiology; cardiometabolic risk factors; evidence-based guidelines; healthcare delivery; quality of care; health system performance

🔗MORE INFORMATION
https://advances.umw.edu.pl/en/closing-implementation-gap

Dr hab. Michał Czapla
Robert Stanisław Śmigiel



Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu

23/03/2026

📢Call for submissions of an Expression of Interest for an Adv Clin Exp Med Special Collection on

Application of stem cells in human medicine – from basic science research to clinical trials 📢

Medicine in the twenty-first century is closely associated with stem cell research, based on advanced in vitro analyzes, the use of model animals, and their application in clinical trials. Experimental research requires understanding the physiological and morphological properties of stem cells and analyzing their ability to divide and differentiate into other cell types. The best-known stem cells are those derived from bone marrow and umbilical cord blood. However, in recent years, stem cells have been discovered in, for example, adipose tissue and Wharton jelly. Stem cells isolated from these tissues, once properly differentiated, are increasingly used for the treatment of bone and neurodegenerative diseases. In recent years, the number of therapies using stem cells has increased significantly. The ability of stem cells to differentiate makes them an increasingly common therapeutic tool in regenerative and reconstructive medicine.

🧠Articles submitted should be related to the topic of stem cells and their use in basic and clinical research. Topics may include:

➡️molecular research involving advanced genomic methods
➡️tissue and cell research
➡️studies on the morphological and physiological properties of stem cells
➡️studies on the proliferative and multidirectional differentiation capacity of stem cells
➡️studies on model animals
➡️use of stem cells in preclinical and clinical research
➡️therapies with stem cell
➡️stem cells in regenerative and reconstructive medicine
➡️stem cells in translational medicine

Review articles describing recent achievements in stem cell medicine, as well as original articles will be accepted.

🔗 MORE INFORMATION:
https://advances.umw.edu.pl/en/application-stem

22/03/2026

📢¡Únete al movimiento para avanzar en la salud mental y el bienestar!📢

Advances in Clinical and Experimental Medicine te invita a enviar tu investigación y artículos de vanguardia en el campo de la salud mental y el bienestar. Buscamos contribuciones innovadoras que amplíen los límites de la comprensión, el tratamiento y la promoción del bienestar mental.

Editores a cargo

Prof. Dr. Raúl Juárez-Vela (Grupo de Investigación en Cuidados (GRUPAC), Facultad de Ciencias de la Salud, Universidad de La Rioja, Logroño, España; ORCID 0000-0003-3597-2048) raul.juarez@unirioja.es

Los temas de interés incluyen, pero no se limitan a:

- Intervenciones terapéuticas innovadoras
- Estrategias para la prevención y promoción del bienestar mental
- Impacto de la salud mental en la calidad de vida
- Nuevos enfoques en el tratamiento de trastornos mentales
- Estudios sobre la relación entre la salud mental y las enfermedades físicas

¿Por qué publicar con nosotros?

- Visibilidad global: Alcanza una amplia audiencia internacional con tu trabajo.
- Revisión rigurosa: Benefíciate de nuestro proceso de revisión por pares de alta calidad.
- Impacto académico: Haz una contribución significativa a un campo vital y dinámico.

Proceso de envío

Como primer paso, solicitamos el envío de una Expresión de Interés con un resumen de artículos originales que aborden los temas mencionados al Editor de Sección de Adv Clin Exp Med: raul.juarez@unirioja.es

El Editor de Sección, junto con el Editor en Jefe, revisará todas las presentaciones y seleccionará aquellas que serán invitadas a enviar un artículo completo. El proceso de envío seguirá el proceso en línea regular de Adv Clin Exp Med. Todos los manuscritos serán enviados a al menos dos revisores independientes.

Fechas y tarifas

- Envío de la Expresión de Interés hasta el 31 de diciembre de 2025 a raul.juarez@unirioja.es
- Invitación para enviar un artículo completo antes del 31 de enero de 2026;
- Envío del artículo completo antes del 31 de marzo de 2026.

Si se acepta, los autores deberán pagar una tarifa (https://advances.umw.edu.pl/en/article-processing-charges/) para cubrir los costos de publicación;

Para autores seleccionados (expertos destacados), es posible reducir o incluso cancelar la tarifa de publicación.

Envía tu manuscrito hoy y únete a la conversación global sobre el mejoramiento de la salud mental y el bienestar. Para más detalles sobre el proceso de envío, visita nuestro sitio web.

¡Esperamos con ansias tus valiosas contribuciones!

22/03/2026

📢New call for submissions📢

📢Join the Movement to Advance Mental Health and Wellbeing!📢

Advances in Clinical and Experimental Medicine invites you to submit your cutting-edge research and articles in the field of Mental Health and Well-being. We are seeking groundbreaking contributions that push the boundaries of understanding, treating, and promoting mental wellbeing.

Handling Editors

Prof. Raúl Juárez-Vela (Group of Research in Care (GRUPAC), Faculty of Health Sciences, University of La Rioja, Logroño, Spain; ORCID 0000-0003-3597-2048) raul.juarez@unirioja.es

Topics of interest include, but are not limited to:

Innovative therapeutic interventions
Strategies for prevention and promotion of mental wellbeing
Impact of mental health on quality of life
New approaches in the treatment of mental disorders
Studies on the relationship between mental health and physical diseases

Why publish with us?

Global Visibility: Reach a wide international audience with your work
Rigorous Review: Benefit from our high-quality peer review process
Academic Impact: Make a significant contribution to a vital and dynamic field

Submission process

As a first step, we ask for submissions of an Expression of Interest with an Abstract of original papers outlining the themes above to Adv Clin Exp Med Section Editor: raul.juarez@unirioja.es

The Section Editor, jointly with the Editor-in-Chief, will review all submissions and select those who will be invited to submit a full paper. The submission process will then follow the regular Adv Clin Exp Med. online process. All manuscripts will be sent to at least two independent reviewers.

Dates and fees

Submission of Expression of Interest until December 31, 2025, to raul.juarez@unirioja.es
Invitation to submit a full paper by January 31, 2026;
Submission of full paper by March 31, 2026.
If accepted, Authors will be required to pay a fee (https://advances.umw.edu.pl/en/article-processing-charges/) to cover publication costs;

For selected Authors (outstanding experts), it is possible to reduce or even cancel the publication fee.

Submit your manuscript today and join the global conversation on enhancing mental health and well-being. For more details on the submission process, visit our website.

We eagerly anticipate your valuable contributions!

21/03/2026

📢 Our new manuscript withdrawal policy 📢

✔️ Withdrawals initiated by authors
Authors may withdraw their manuscript at any stage of the editorial process. However, 2 conditions must be met for a withdrawal request to be processed:

– A clear and specific reason for withdrawal must be provided – both in the Editorial System and in the withdrawal statement.
– All authors must consent to the withdrawal. A statement signed by all authors should be scanned and submitted as a PDF file to the editorial office at [redakcja@umw.edu.pl] and/or uploaded to the Editorial System as an Additional File.

Until these conditions are fulfilled, the manuscript cannot be considered withdrawn.

Please note that if you intend to resubmit the manuscript, it is advisable to address necessary corrections during the initial verification or peer-review process rather than withdrawing the submission. A withdrawn and resubmitted manuscript is assessed as an entirely new submission – the previous (withdrawn) submission is not taken into consideration; in consequence, it prolongs the whole assessment process.

✔️ Withdrawals initiated by the editorial office
A manuscript will be withdrawn by the editorial office if:

– After acceptance, evidence for scientific misconduct is found
– Authors fail to sign the license agreement form within 30 days after acceptance
– Authors fail to pay the article processing charge (APC) within 30 days after acceptance
– Authors repeatedly fail to correct the galley proof or cease communication with the editorial office in this regard for more than 30 days.

✔️ Refund policy (withdrawals after the APC has already been paid)
Adv Clin Exp Med does not refund the APC once it has been paid. This policy applies in the following cases:
– When authors withdraw a manuscript after acceptance and payment of the APC (but before publication), regardless of the reason for withdrawal.
– When the manuscript is withdrawn by the editors due to the authors' failure to adequately correct errors or an attempt to change the authorship after acceptance (which violates our policy).
– When articles are retracted after publication due to author error or misconduct.
The APC is not a publication fee but an article-processing charge—it covers the costs of peer review, statistical review, editing, and typesetting. Since the majority of this work is completed before the APC is paid, refunds cannot be issued.
In exceptional cases, authors may appeal to the Editor-in-Chief, whose decision is final.

✔️ Withdrawal after acceptance due to funding limitations
We ask that authors submit papers to our journal only if they have funding. Before submitting, please make sure that you have the necessary funds to pay the APC in case of acceptance.
https://advances.umw.edu.pl/en/article-processing-charges/
Please note that our journal offers neither APC waivers nor discounts, including discounts for researchers from lower-income countries and countries against which international sanctions have been imposed.

✔️ Ethical considerations concerning withdrawals
Before you withdraw a paper, please consider that the editor and reviewers have likely already invested significant time reviewing your manuscript. The further along in the paper's peer-review process, the greater the ethical concern with withdrawing a manuscript, given that a considerable amount of time has been spent on the paper by reviewers, editors, and editorial assistants. Please let us know before withdrawing if there is anything we can do to avoid the withdrawal. We are happy to work with authors to remove any perceived barriers to publishing.
Please note that it is unethical and considered violating scientific norms (i.e., poor scientific practice bordering on scientific misconduct) to submit a paper still under consideration at a journal A to a different journal B. If you have already created a duplicate submission, please withdraw your paper from the other journal immediately and only submit it after receiving confirmation that your withdrawal request has been successfully processed. Otherwise, according to international best practices on publication ethics, a withdrawal may violate the research community's norms and may have negative consequences for the authors.

✔️ Withdrawing a published paper
Withdrawal is possible during the initial verification process, from the peer-review process or after acceptance, before publication. Withdrawing a paper after publication is called a retraction, please see https://advances.umw.edu.pl/en/appeals-complaints-corrections-retractions-commentaries for retraction policies.